Surgical Endoscopy

, Volume 25, Issue 2, pp 658–660 | Cite as

Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery

Letter
First Online:
  • 69 Downloads

Keywords

Rectal Cancer Laparoscopic Surgery Total Mesorectal Excision Robotic Surgery KRAS Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Disclosure

Authors John Spiliotis and Odysseas Zoras have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc 23(8):1818–1824CrossRefPubMedGoogle Scholar
  2. 2.
    Garber AM, Tunis SR (2009) Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360(19):1925–1927CrossRefPubMedGoogle Scholar
  3. 3.
    Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J (2008) Long-term outcome of laparoscopic surgery for colorectal cancer: a Cochrane systematic review of randomised controlled trials. Cancer Treat Rev 34(6):498–504CrossRefPubMedGoogle Scholar
  4. 4.
    Ziogas D, Polychronidis A, Kanellos I, Roukos DH (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696 (author reply 697)CrossRefPubMedGoogle Scholar
  5. 5.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMedGoogle Scholar
  6. 6.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRefGoogle Scholar
  8. 8.
    Ziogas D, Roukos D (2009) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefGoogle Scholar
  9. 9.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830CrossRefPubMedGoogle Scholar
  10. 10.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMedGoogle Scholar
  14. 14.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMedGoogle Scholar
  15. 15.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  16. 16.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author reply 1363)CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH, Lykoudis E, Liakakos T (2009) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361CrossRefGoogle Scholar
  20. 20.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197 (author reply 198)CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMedGoogle Scholar
  24. 24.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):1555–1556PubMedGoogle Scholar
  27. 27.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMedGoogle Scholar
  29. 29.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMedGoogle Scholar
  34. 34.
    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of SurgeryMetaxa Anticancer HospitalPeiraeusGreece
  2. 2.Department of General SurgeryUniversity Hospital of Heraklion, Medical School, University of CreteHeraklionGreece

Personalised recommendations